.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Mallinckrodt
Farmers Insurance
Chinese Patent Office
Accenture
Medtronic
Deloitte
Daiichi Sankyo
Fish and Richardson
Colorcon

Generated: June 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,536,427

« Back to Dashboard

Summary for Patent: 6,536,427

Title: Inhalation device
Abstract:An inhalation device is described for use with a medicament pack in which at least one container for medicament in powder form is defined between two sheets peelably secured to one another. The device comprises means for peeling the sheets apart at an opening station to open the container; and an outlet, communicating with the opened container, through which a user can inhale medicament in powder form from the opened container.
Inventor(s): Davies; Michael Birsha (Ware, GB), Hearne; David John (Luton, GB), Rand; Paul Kenneth (Letchworth, GB), Walker; Richard Ian (Ware, GB), Palmer; James Barry Douglas (Greenford, GB)
Assignee: Glaxo Group Limited (Middlesex, GB)
Application Number:09/925,614
Patent Claim Types:
see list of patent claims
Compound; Device;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,536,427

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom90 04781Mar 02, 1990

International Patent Family for Patent: 6,536,427

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea100244004► Subscribe
Luxembourg87898► Subscribe
Netherlands9100381► Subscribe
Netherlands193930► Subscribe
Greece910100096► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Queensland Health
Baxter
Cerilliant
Citi
Fuji
Mallinckrodt
McKinsey
Cantor Fitzgerald
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot